Work

Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.3_suppl.308

Authors: Tareq Al Baghdadi, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Kathleen J Yost, Vi Kien Chiu, Herbert Leon Duvivier, Meredith McKean, Jens Rueter, Mark A. Taylor, Gina N. Grantham, Abby Gregory, Dominique C. Hinshaw, Susan Halabi, Richard L. Schilsky

Institutions: Michigan Cancer Research Consortium, American Society of Clinical Oncology, Angeles Clinic and Research Institute, City of Hope, Sarah Cannon, Tennessee Oncology, Jackson Laboratory, Louisiana Cancer Research Center, Swiss Cancer Center Léman, Duke Medical Center

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W4391096741

Cites:

Cited by: 1

Related to: 10